Meta-analysis finds Xingpi Yanger Granule plus conventional therapy reduces nocturnal enuresis frequency in children

Photo by Navy Medicine / Unsplash

Frontiers in Medicine Published May 12, 2026 Medically reviewed May 12, 2026 DOI ↗ By Dr. Sofia Müller, MD · Lifespan & Whole-Person Care

Key Takeaway

Consider the potential benefit of Xingpi Yanger Granule as adjunctive therapy for nocturnal enuresis, but note the limited evidence and unreported safety data.

This systematic review and meta-analysis of randomized controlled trials evaluated the efficacy of Xingpi Yanger Granule combined with conventional medication versus conventional therapy alone for nocturnal enuresis (NE) in children. The analysis included 1,138 patients across multiple trials. The primary outcome was the frequency of NE episodes.

The pooled analysis showed a notable reduction in NE frequency favoring the combination therapy, with a mean difference of 1.55 (95% CI 0.66 to 2.43). However, the p-value was not reported, and the confidence interval is relatively wide, indicating some uncertainty in the estimate.

The authors did not report on adverse events, serious adverse events, or discontinuations, and the follow-up duration was not specified. Limitations of the meta-analysis were not explicitly discussed, but the absence of safety data and the wide confidence interval warrant caution.

For clinicians, this meta-analysis suggests a potential benefit of adding Xingpi Yanger Granule to conventional therapy for children with NE, but the evidence is limited by incomplete reporting and lack of safety information. Further high-quality trials with longer follow-up and standardized outcomes are needed before routine clinical adoption.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

ObjectiveThis systematic review aims to determine the clinical efficacy and safety of Xingpi Yanger Granule (XPYEG) in combination with conventional medication for the treatment of Nocturnal Enuresis based on existing data.MethodsA systematic search was conducted across the China National Knowledge Infrastructure (CNKI), Wanfang Data, China Biomedical Literature Database (CBM), VIP, PubMed, Embase, Cochrane Library, and Web of Science databases to identify relevant RCTs on the auxiliary treatment of NE in children using XPYEG from the inception of each database up to August 2025. The risk of bias in the included RCTs was assessed using the Cochrane Risk of Bias tool (ROB2). Meta-analysis was performed using Review Manager, and the sensitivity analysis was conducted using Stata 18 software. The quality of evidence was evaluated with the GRADE approach. Furthermore, Trial Sequential Analysis (TSA) was employed to determine the required sample size and to verify the reliability of the findings. The review protocol was registered and published on PROSPERO (CRD420251156842).ResultsThis study included 12 RCTs involving 1,138 patients. Compared with conventional therapy alone, the combination of XPYEG significantly improves core symptoms, which is clinically significant. Core Symptom and Functional Outcomes: Compared with the control group, adjunctive XPYEG therapy resulted in a notable reduction in the frequency of NE [MD = 1.55, 95% CI (0.66, 2.43), P